Asian Pacific Journal of Cancer Prevention

  • 제15권24호
  • /
  • Pages.10997-10998
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Expectations of Response from Octreotide Therapy in Recurrent Phosphaturic Mesenchymal Tumors - Do They Reflect Reality?

  • Ulas, Arife (Ankara Ataturk Training and Research Hospital) ;
  • Dede, Didem Sener (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research And Training Hospital, Department of Medical Oncology) ;
  • Sendur, Mehmet Ali Nahit (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research And Training Hospital, Department of Medical Oncology) ;
  • Akinci, Muhammed Bulent (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research And Training Hospital, Department of Medical Oncology) ;
  • Yalcin, Bulent (Yildirim Beyazit University, Faculty of Medicine, Ataturk Research And Training Hospital, Department of Medical Oncology)
  • 발행 : 2015.01.22
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Carpenter TO (2003). Oncogenic osteomalacia - a complex dance of factors. N Engl J Med, 348, 1705-8. https://doi.org/10.1056/NEJMe030037
  2. Clifton-Bligh RJ, Hofman MS, Duncan E (2013). Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab, 98, 687-94. https://doi.org/10.1210/jc.2012-3642
  3. Folpe AL, Fanburg-Smith JC, Billings SD, et al (2004). Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol, 28, 1-30. https://doi.org/10.1097/00000478-200401000-00001
  4. Guo LJ, Tang CW (2014). Somatostatin analogues do not prevent carcinoid crisis. Asian Pac J Cancer Prev, 15, 6679-83 https://doi.org/10.7314/APJCP.2014.15.16.6679
  5. Houang M, Clarkson A, Sioson L, et al (2013). Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol Dec, 44, 2711-8. https://doi.org/10.1016/j.humpath.2013.07.016
  6. Jan de Beur SM, Streeten EA, Civelek AC (2002). Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet, 359, 761-3. https://doi.org/10.1016/S0140-6736(02)07846-7
  7. Jan de Beur SM (2005). Tumor-induced osteomalacia. JAMA, 294, 1260-7 https://doi.org/10.1001/jama.294.10.1260
  8. Jonsson KB, Zahradnik R, Larsson T, et al (2003). Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med, 348, 1656-63. https://doi.org/10.1056/NEJMoa020881
  9. Paglia F, Dionisi S, Minisola S (2002). Octreotide for Tumor- Induced Osteomalacia N Engl J Med, 30, 1748-9
  10. Reubi JC, Waser B, Laissue JA, Gebbers JO (1996). Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res, 56, 1922-31
  11. Rodrigues NR, Calich AL, Etchebehere M, et al (2014). Whole- Body 99mTc-Octreotide Scintigraphy with SPECT/CT to Detect Occult Tumor Inducing Paraneoplastic Osteomalacia. Clin Nuc Med, 22.
  12. Seufert J, Ebert K, Muller J et al (2001). Octreotide for tumorinduced osteomalacia. N Engl J Med, 345,1883 https://doi.org/10.1056/NEJMoa010839
  13. Weider N, Santa Cruz D (1987). Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer, 59, 1442-54. https://doi.org/10.1002/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q
  14. Wynick D, Anderson JV, Williams SJ, et (1989). Resistance to metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol, 30, 385-8. https://doi.org/10.1111/j.1365-2265.1989.tb00436.x